G-BA assessment of orphan drug gene therapies, Zolgensma and Libmeldy
The gene therapies Zolgensma and Libmeldy, both, are targeting very rare, severe, genetic diseases in children. The G-BA has now assessed the
Tag: G-BA
Why did the G-BA assess Trimbow now?
Trimbow was launched onto the German market in 2017. So why did the G-BA assess its benefit now? You likely know that
Change in morbidity factor means more GPs are needed in Germany
Identifying amount of required healthcare The G-BA developed the needs planning directive (German: Bedarfsplanungs-Richtlinie) to give national rules on “how much” SHI-funded
Who are the members of the G-BA?
The G-BA has 13 voting members forming the so-called plenum. The representatives of care providers are only entitled to vote on topics
Three new methods were added to the catalogue of SHI funds
Before a new diagnostic and treatment method can be offered and reimbursed in the outpatient sector, two important steps need to be